Merck Cancidas Label Should Highlight Cyclosporine Data - FDA Committee
Executive Summary
Labeling for Merck's antifungal Cancidas should include all available data on concomitant use with cyclosporine, although coadministration of the products is not recommended, FDA's Antiviral Drug Products Advisory Committee said Jan. 10.
You may also be interested in...
Merck Will Study Cancidas/Antifungal Combinations In Phase IV Trials
Merck will study Cancidas in combination with other antifungals for invasive aspergillosis treatment.
Merck Will Study Cancidas/Antifungal Combinations In Phase IV Trials
Merck will study Cancidas in combination with other antifungals for invasive aspergillosis treatment.
Invasive Aspergillosis Trial May Include Non-Licensed Comparator - FDA
FDA is considering use of liposomal amphotericin B products as a comparator in first-line invasive aspergillosis trials, FDA Special Pathogens & Immunologic Drug Products Division Director Mark Goldberger, MD, indicated Jan. 10.